Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Christin L. Hertz"'
Publikováno v:
Cell Reports Medicine, Vol 2, Iss 9, Pp 100387- (2021)
Summary: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are used for the treatment of type 2 diabetes. Whether clinically important responses and adverse events (AEs) are dependent on the route of administration has not been determined. We demon
Externí odkaz:
https://doaj.org/article/9151662c784843edaf0fc0f0151e62d7
Autor:
Johannes Rødbro Busch, Sofie Lindgren Christiansen, Kristine Boisen Olsen, Jytte Banner, Gonçalo Espregueira Themudo, Jeppe Dyrberg Andersen, Christin L. Hertz, Niels Morling, Martin Christensen
Publikováno v:
Christiansen, S L, Andersen, J D, Themudo, G E, Hertz, C L, Busch, J R, Christensen, M R, Olsen, K B, Banner, J & Morling, N 2021, ' Genetic investigations of 100 inherited cardiac disease-related genes in deceased individuals with schizophrenia ', International Journal of Legal Medicine, vol. 135, no. 4, pp. 1395-1405 . https://doi.org/10.1007/s00414-021-02595-y
Cardiac diseases and sudden cardiac death (SCD) are more prevalent in individuals diagnosed with schizophrenia compared to the general population, with especially coronary artery disease (CAD) as the major cardiovascular cause of death. Antipsychotic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85dd74ead24b55f3f69ca9f63abe11ad
https://doi.org/10.1007/s00414-021-02595-y
https://doi.org/10.1007/s00414-021-02595-y
Autor:
Kamlesh Khunti, John B. Buse, Mette Gislum, Thomas Bo Jensen, Matthew J Crowley, Richard E. Pratley, Christin L. Hertz, Ofri Mosenzon
Publikováno v:
Diabetes Therapy
Introduction The efficacy and safety of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, were investigated in patients with type 2 diabetes (T2D) in the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) programme. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c74e5615ec6b1eb8d7560050c7cb76f8
https://doi.org/10.1007/s13300-020-00994-9
https://doi.org/10.1007/s13300-020-00994-9
Autor:
Stephen C. Bain, Emina Mocevic, Lise Lotte N. Husemoen, Rikke B. Nordsborg, Johanne Spanggaard Piltoft, Christin L. Hertz, Kamlesh Khunti
Publikováno v:
Diabetic Medicine. 39
AIMS To characterise the cardiovascular risk of people with type 2 diabetes without established cardiovascular disease but with risk factors, relative to those with established cardiovascular disease, to provide information on which patients could be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22811b9caf407c193972430628da5530
https://doi.org/10.1111/dme.14697
https://doi.org/10.1111/dme.14697
Autor:
Yutaka Seino, Yuichiro Yamada, Daisuke Yabe, Jiro Nakamura, Christin L. Hertz, Anne Møller Nielsen, Hiroshi Horio
Publikováno v:
Diabetes, obesitymetabolism. 24(2)
A post-hoc exploratory analysis of the PIONEER 9 and 10 trials evaluated the effect of baseline age (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77dd6cdcc566fb919344d6c768ef38c9
https://pubmed.ncbi.nlm.nih.gov/34622548
https://pubmed.ncbi.nlm.nih.gov/34622548
Autor:
Filip K. Knop, Eduard Montanya, Julio Rosenstock, Bertrand Cariou, Christin L. Hertz, Morten Abildlund Nielsen, Erik Christiansen
Publikováno v:
Diabetes. 70
A standard objective in the management of T2D is the achievement and maintenance of HbA1c targets, but the duration of time that patients spend within glycemic control targets has not been previously reported for oral semaglutide (sema). In this expl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7820727236c1091272daad482f0aad85
https://doi.org/10.2337/db21-670-p
https://doi.org/10.2337/db21-670-p
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e66881 (2013)
AIMTo investigate the personality in very preterm individuals (VPT; gestational age, GA, METHODDemographic data were extracted for all individuals born in Denmark in 1974-76 and 1980-82. From each period one index-group each comprising 150 individual
Externí odkaz:
https://doaj.org/article/a95daae714c742e3b8019b5d53872b50
932-P: Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program
Autor:
Vanita R. Aroda, Bertrand Cariou, Eduard Montanya, Christin L. Hertz, Robert Bauer, Mark Warren, Rasmus Sørrig
Publikováno v:
Diabetes. 69
In an exploratory analysis of 7 global phase 3a trials (PIONEER 1-5, 7, and 8) we evaluated the effect of age at baseline on efficacy ( Disclosure V.R. Aroda: Consultant; Self; Duke, Novo Nordisk Inc., Sanofi. Employee; Spouse/Partner; Merck & Co., I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::400717b28e01b83460ad26f888d7f0c1
https://doi.org/10.2337/db20-932-p
https://doi.org/10.2337/db20-932-p
Autor:
Tina Vilsbøll, Vincent C. Woo, Morten Abildlund Nielsen, Kathleen M. Dungan, Christin L. Hertz, Rasmus Sørrig, Linda Mellbin
Publikováno v:
Diabetes. 69
The PIONEER phase 3 program investigated glycemic response and other efficacy endpoints in patients (pts) with type 2 diabetes randomized to the glucagon-like peptide-1 analog oral semaglutide (sema; 3, 7 or 14 mg once daily), placebo (pbo) or an act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c01905a9a9ed21d701016c2fcf6f4590
https://doi.org/10.2337/db20-964-p
https://doi.org/10.2337/db20-964-p